Results 11 to 20 of about 4,864 (135)
Meningococcal Vaccines: Challenges and Prospects [PDF]
Vaccines, 2020 Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...]
Priyal Bagwe +5 more
openaire +5 more sources
Vaccines against Meningococcal Diseases [PDF]
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W, and Y).
Mariagrazia Pizza +2 more
openaire +4 more sources
Meningococcal vaccine evolution
Clinical Management Issues, 2012 Neisseria meningitidis is a leading cause of bacterial sepsis and meningitis worldwide. Although polysaccharide and glycoconjugate vaccines have been developed for serogroups A, C, Y and W-135, currently there are no broadly effective vaccines available for the prevention of meningococcal B disease.
BONA, Gianni, Guidi C.
openaire +6 more sources
A space-time conditional intensity model for invasive meningococcal disease occurrence [PDF]
Biometrics 68, 607--616, 2015 A novel point process model continuous in space-time is proposed for quantifying the transmission dynamics of the two most common meningococcal antigenic sequence types observed in Germany 2002-2008. Modelling is based on the conditional intensity function (CIF) which is described by a superposition of additive and multiplicative components.
arxiv +1 more source
Human Vaccines & Immunotherapeutics, 2012 Meningococcal meningitis is caused by Neisseria meningitidis, a gram-negative, aerobic, encapsulated diplococcus. Meningococci are divided into numerous serogroups based on the composition of their capsular polysaccharide (Ps) antigens. At least 13 serogroups have been described: A, B, C, D, 29E, H, I, K, L, W-135, X, Y and Z.
Pardeep Khanna, Ramesh Verma
openaire +3 more sources
Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia [PDF]
New England Journal of Medicine, 2020 BACKGROUND: The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based vaccine that is licensed to protect against invasive group B meningococcal disease. However, its role in preventing transmission and, therefore, inducing population (herd) protection is uncertain.
Martin C. J. Maiden +17 more
openaire +5 more sources
VaccineLies: A Natural Language Resource for Learning to Recognize Misinformation about the COVID-19 and HPV Vaccines [PDF]
arXiv, 2022 Billions of COVID-19 vaccines have been administered, but many remain hesitant. Misinformation about the COVID-19 vaccines and other vaccines, propagating on social media, is believed to drive hesitancy towards vaccination. The ability to automatically recognize misinformation targeting vaccines on Twitter depends on the availability of data resources.
arxiv
The Impact of Vaccination Behavior on Disease Spreading Based on Complex Networks [PDF]
arXiv, 2021 Vaccination is an effective way to prevent and control the occurrence and epidemic of infectious diseases. However, many factors influence whether the residents decide to get vaccinated or not, such as the efficacy and side effects while individuals hope to obtain immunity through vaccination.
arxiv
COVID-19 Vaccine Hesitancy and Information Diffusion: An Agent-based Modeling Approach [PDF]
arXiv, 2021 Despite the unprecedented success in the rapid development of several effective vaccines against the Cov-SARS-2, global vaccination rollout efforts suffer from vaccine distribution inequality and vaccine acceptance, leading to insufficient public immunity provided by the vaccine products.
arxiv
Impact of vaccination on meningococcal epidemiology [PDF]
Human Vaccines & Immunotherapeutics, 2015 Neisseria meningitidis may cause invasive disease (meningitis and sepsis), leading to considerable disease burden and mortality. However, effective vaccines are available against most pathogenic serogroups. Large-scale vaccination campaigns with the MCC vaccine conducted in UK and with MenAfriVac in the Sahel have clearly demonstrated the direct and ...
Stefanelli P, Rezza G
openaire +3 more sources